490 related articles for article (PubMed ID: 26566351)
1. Respiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea.
Lee JH; Kim CS; Chang YS; Choi JH;
J Korean Med Sci; 2015 Oct; 30 Suppl 1(Suppl 1):S104-10. PubMed ID: 26566351
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
3. Use of Medical Resources by Preterm Infants Born at Less than 33 Weeks' Gestation Following Discharge from the Neonatal Intensive Care Unit in Korea.
Lee JH; Chang YS;
J Korean Med Sci; 2015 Oct; 30 Suppl 1(Suppl 1):S95-S103. PubMed ID: 26566364
[TBL] [Abstract][Full Text] [Related]
4. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
Han YM; Seo HJ; Choi SH; Jung YJ; Ahn SY; Yoo HS; Sung SI; Shim JW; Lee YK; Ko SY; Shin SM; Hwang JH; Lee JH; Choi BM; Kim ES; Jeon JH; Kim SS; Chang YS; Park WS
J Korean Med Sci; 2015 Jul; 30(7):924-31. PubMed ID: 26130956
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.
Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS
Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model.
Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY
Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
8. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.
Torchin H; Rousseau J; Marchand-Martin L; Truffert P; Jarreau PH; Ancel PY
Arch Pediatr; 2018 Feb; 25(2):89-94. PubMed ID: 29395887
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab in infants with gestational age < or = 28 weeks and bronchopulmonary dysplasia.
Parmigiani S; Ubaldi A; Capuano C; Massinissa Magini G; Bianchi ME
Acta Biomed Ateneo Parmense; 2001; 72(5-6):109-13. PubMed ID: 12233268
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
14. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.
Liese JG; Grill E; Fischer B; Roeckl-Wiedmann I; Carr D; Belohradsky BH;
Eur J Pediatr; 2003 Apr; 162(4):230-6. PubMed ID: 12647195
[TBL] [Abstract][Full Text] [Related]
16. Lower respiratory tract illness and RSV prophylaxis in very premature infants.
Lacaze-Masmonteil T; Truffert P; Pinquier D; Daoud P; Goldfarb G; Vicaut E; Fauroux B
Arch Dis Child; 2004 Jun; 89(6):562-7. PubMed ID: 15155404
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
[TBL] [Abstract][Full Text] [Related]
18. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
20. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.
Abraha HY; Lanctôt KL; Paes B
Expert Rev Respir Med; 2015; 9(6):779-99. PubMed ID: 26457970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
